2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2347

Effectiveness of Shared Decision Making in Systemic Lupus Erythematosus Patients at OSU

Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives

9:00AM-11:00AM: Abstract Number: 2032

Effector T Helper Cell Differentiation and Cytokine Secretion Are Increased in Young Children with Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2210

Effects of Anti-Citrullinated Peptide Antibody (ACPA) on Bone Microstructure in Rheumatoid Arthritis: A HR-pQCT Study

Imaging of Rheumatic Diseases Poster III: Other Modalities

9:00AM-11:00AM: Abstract Number: 2751

Effects of Baseline Prednisone Dose on Remission and Disease Flare in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Phase 3 Randomized Controlled Trial

Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2058

Effects of Fatty Acid Supplementation in Modulation of Gut Microbiome and T-Regulatory Cells in Health and Psoriatic Disease

Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: L03

Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee

Late-Breaking Abstract Poster Session

9:00AM-11:00AM: Abstract Number: 2462

Efficacy and Safety in the Middle-LONG Period of Rituximab in the Treatment of Diffuse Interstitial Pulmonary Disease Associated with Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2563

Efficacy and Safety of a Potent and Highly Selective Oral Tyrosine Kinase 2 Inhibitor, BMS-986165, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Placebo-Controlled Trial

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2559

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: L12

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Prior Inadequate Response or Intolerance to 1 or 2 Tumor Necrosis Factor Inhibitors

Late-Breaking Abstract Poster Session

9:00AM-11:00AM: Abstract Number: 2558

Efficacy and Safety Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the 48-Week Run-in Part of a Withdrawal Study (NCT02505542)

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2598

Efficacy of Anti-Tumor Necrosis Factor (TNF) Alpha Therapy, in Patients with Spondylarthritis in the University Center of Rouen in France, Divived to the Berlin Algorithm Modified By the Assessement Spondylarthritis Group: A Ten Years Retrospective Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2560

Efficacy of Guselkumab in Psoriasis Patients with Self-Reported Psoriatic Arthritis with Involvement of the Scalp, Nails, Hands, and Feet: A Pooled Analysis from 2 Pivotal Phase 3 Psoriasis Studies

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2520

Efficacy of the Reference Biologic Agents in Two Different Types of Randomized Clinical Trials: 1/ the Ones Comparing Their Efficacy Vs. Placebo and 2/ the Ones Comparing Their Efficacy Vs. Biosimilar in Rheumatoid Arthritis: A Systematic Review of Literature and Meta-Analysis

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 2603

Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].